melanoma

dart board miss failure
Biotech

Replimune to lay off staff after 'disappointing' second rejection

Even with additional data and a new team of reviewers, the FDA still found fault with the trials for Replimune's oncolytic virus.
Darren Incorvaia Apr 10, 2026 1:56pm
Prune

Pfizer drops another early cancer candidate from Seagen

Mar 19, 2026 12:56pm
Bahija Jallal

After R&D head exits, Immunocore CEO pairs ambition with caution

Feb 13, 2026 12:44pm
Completing steps towards success checkmark on cubes symbolizing progress

Merck, Moderna sustain 49% melanoma risk reduction at 5 years

Jan 20, 2026 8:50am
gold arrow pointing upward forward

Replimune's stock spikes 100% on FDA acceptance of resubmission

Oct 20, 2025 5:33pm
BioNTech

BioNTech fades cancer vax in late-stage melanoma setting

Oct 20, 2025 3:01pm